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Conclusion:
 
 Thromboaspiration should be proposed systematically in case
of STEMI to reduce the risk of no reflow particularly in the presence of clin-
ical or angiographic predictive factors of this phenomenon.
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Background: 
 
Recent data suggest that fractional flow reserve (FFR) is
useful in guiding coronary revascularization. There is however currently no
large report of the use of this technology in France, in particular its impact on
the decision of coronary revascularization.
 
Methods: 
 
The R3F registry investigated the use of FFR in 20 French cen-
ters from October 2008 to June 2010. To investigate this issue the investiga-
tors defined prospectively their revascularization strategy "a priori" before
performing the FFR. This was compared to the final strategy applied to the
patient after performing the FFR. The results of the first 945 consecutive
patients are presented.
 
Results:
 
 75% of patients were males with a mean age of 65±10 years, 37%
were diabetics and 19% had a recent ACS. Patients had non-significant (<
50% stenosis) angiographic coronary artery disease (14%), significant (>50%)
angiographic 1-vessel (37%), 2-vessel (30%) or 3-vessel disease (19%). The
strategy defined “a-priori” by the investigators was medical therapy (52%),
PCI (37%), and CABG (11%). After the results of FFR the final strategy was
medical therapy in 58% and coronary revascularization in 42% (PCI in 31%
and CABG in 11%). Interestingly in 45% of cases the strategy defined “a
priori” was modified by the results of the FFR: 
1) In 36% of the patients in which a medical therapy was planed “a priori” the
strategy was modified for PCI (26%) or CABG (10%); 
2) In 58% of the patients in which a PCI was considered “a priori” the strategy
was modified for medical therapy (50%) or CABG (8%); 
3) In 68% of the patients in which a CABG was considered “a priori” the
strategy was modified for medical therapy (64%) or PCI (4%).
 
Conclusion:
 
 The present report, based on a large French multicenter reg-
istry, demonstrated that although FFR had little impact on the overall rate of
revascularization, it modified the individual decision in almost 1 out of 2
patients.
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Several in-hospital complications (HC) could impair the clinical course of
tako-tsubo syndrome (TTS). 
 
Objective:
 
 to assess the clinical and echocardiographic predictors of HC in
TTS. 
 
Methods:
 
 37 consecutive patients (pts) (mean age, 69 ± 10 years, 35
women) with a typical TTS according to the Mayo Clinic criteria underwent
prospectively a comprehensive transthoracic Doppler-echocardiography
including the non invasive assessment of coronary flow reserve (CFR), mea-
sured in the distal part of the left anterior descending artery using intravenous
adenosine infusion, at the acute phase (within 24-48 h of symptom onset) and
after recovery (1 month apart). Clinical and biochemical parameters were also
assessed. HC were defined as cardiogenic shock, or thrombo-embolic event. 
 
Results:
 
 HC occurred in 8 cases (22%). Pts with HC, compared to pts
without HC, were more frequently diabetics (63% vs. 21%, p < 0.05), and had
at the acute phase a more severely impaired CFR (1.8 ± 0.5 vs. 2.3 ± 0.4,
p<0.01), left ventricular (LV) ejection fraction (33 ± 8 % vs. 41 ± 9 %,), wall
motion score index, and LV systolic volume/m
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 (all, p < 0.05), Age, frequency
of ECG ST-segment elevation at presentation, troponin peak, and preexisting
beta-blockers use, were not significantly different in pts with and without HC
(all, p = NS). The in-hospital length of stay was longer in the former group (
p < 0.05). After recovery, CFR improved significantly in both groups. How-
ever, the magnitude of improvement was higher in pts with HC as compared
to pts without HC (74 % vs. 27 %, p < 0.05) leading to final value of CFR
similar in both groups (2.9 ± 0.4 vs. 3.1 ± 0.6, p = NS). In multivariate anal-
ysis, the only independent predictor of HC was acute CFR (p = 0.028). Using
a ROC curve analysis a CFR < 1.9 was the best cut-off to predict HC with a
sensitivity of 75% and specificity of 86%, (AUC 0.76, p < 0.01). With a mean
follow-up of 24 ± 10 months, one patient died in the group of HC vs. none in
the other group.
 
Conclusion:
 
 CFR is an independent predictor of HC, suggesting that the
impairment of the coronary microcirculation is important at the acute phase of
TTS. 
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Background:
 
 Microvascular obstruction (MVO) at the acute phase of
myocardial infarction (MI) is associated with greater myocardial damage, left
ventricular (LV) impairment and higher mortality. We compared the impact of
early and late microvascular obstruction (MVO) as assessed by 3-T cardiac
magnetic resonance imaging (MRI) at the acute phase of MI on LV remod-
eling at 6 months.
 
Methods:
 
 We included 51 consecutive patients (pts) with no previous his-
tory of cardiovascular disease, and presenting for first MI with or without ST
elevation. Infarct size and extent of no-reflow were evaluated by 3-T MRI
during acute phase by early and late hyperenhancement imaging at 3 and 15
min after gadolinium injection. Extent of no-reflow at 3 minutes (early MVO)
and 15 minutes (late MVO) was measured. Follow-up MRI was performed at
6 months. Systolic and diastolic LV volumes, as well as LV ejection fraction
and infarct size were compared at baseline and 6 months.
 
Results:
 
 Incidence of early MVO was 56% vs 43% for late MVO. There
was a significant difference in extent of no-reflow between early and late
MVO (7.8±4% vs 5.4±4%, p<0.0001, early vs late respectively). There was
also a significant difference in LV evolution at 6 months between pts with and
without no-reflow (p<0.05). In pts who showed no-reflow at 3 minutes only,
but not at 15 minutes, ventricular dilatation was observed at 6 month follow-
up of a magnitude similar to that observed in pts with persistent no-reflow at
15 minutes.
 
Conclusion:
 
 Incidence of MVO is higher when assessed at 3 minutes,
rather than at 15 minutes. In this context, systematic early MVO evaluation
could help identify a larger group of pts at risk of unfavourable evolution,
because when MVO is evaluated at 15 minutes, pts who had no-reflow at 3
minutes that subsequently resolved, go unidentified. The presence of MVO is
associated with LV dilatation at 6 months follow-up, regardless of whether no-
reflow was present at 3 minutes only, or persistent at 15 minutes.
